Uveitis

The preclinical data was presented during the 2025 ARVO meeting.

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.

This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”

ACELYRIN will not make any additional internal investment in developing izokibep.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.

Dr. Arepalli discussed a course focused on ocular conditions related to pregnancy and postpartum care, presented at the American Academy of Ophthalmology (AAO) meeting.

Steven Yeh, MD, discussed his recent presentation at the Retina Society meeting and shared what he is looking forward to presenting at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

Ashkan Abbey, MD, spoke with Modern Retina about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.

Danny Mammo, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss the effect of suprachoroidal triamcinolone acetonide in non-infectious uveitis, patients which he is presenting at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The UME module adds to the list of ophthalmic diseases available in the dataset.

David Almeida, MD, PhD, MBA, presented on gene therapy associated uveitis at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.

The almost 474,000 participants in the study had been diagnosed with uveitis between January 1, 2015, and February 25, 2021 in South Korea.

NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with more than 1400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified.

The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye.

Researchers at the Eye Clinic of the University Hospital Bonn (UKB) and the University of Bonn have tested a new imaging method for monitoring intermediate uveitis.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.